Dose fractionation and tumour repopulation in radiotherapy for bladder cancer
- PMID: 1924851
- DOI: 10.1016/0167-8140(91)90033-d
Dose fractionation and tumour repopulation in radiotherapy for bladder cancer
Abstract
Local control of the 77 transitional cell carcinoma of the bladder was analysed with respect to total dose after normalization for variations in fraction size and to overall treatment time. For the TCD50 of 63.3 Gy protraction of overall treatment time from 40 to 55 days average gave the decrease in local control rate from 50% to about 5%. The decrease in local tumour control with extension of overall treatment time likely reflects accelerated tumour repopulation during the treatment. To determine the time onset of the accelerated tumour clonogen repopulation, data taken from the literature were analysed. Results show that on average tumour clonogen repopulation in transitional cell cancer of the bladder accelerates after a lag period of about 5-6 weeks after the start of treatment and that a dose increment of 0.36 Gy per day is required to compensate for this repopulation. Such a dose increment is consistent with about 5-8 day clonogen doubling time. It suggests that overall treatment time is an important factor in the dose fractionation and protraction of time may have a significant impact on treatment outcome. Thus, radiotherapy for bladder cancer should be completed as soon as possible and total dose for high probability of local tumour control should consequently be delivered in more than 5 fractions per week.
Comment in
-
Overall treatment time in the radiotherapy of transitional cell cancer of the bladder.Radiother Oncol. 1992 Apr;23(4):270-1. doi: 10.1016/s0167-8140(92)80135-6. Radiother Oncol. 1992. PMID: 1609134 No abstract available.
Similar articles
-
The hazard of accelerated tumor clonogen repopulation during radiotherapy.Acta Oncol. 1988;27(2):131-46. doi: 10.3109/02841868809090333. Acta Oncol. 1988. PMID: 3390344
-
A randomised trial of accelerated radiotherapy for localised invasive bladder cancer.Radiother Oncol. 2005 Apr;75(1):34-43. doi: 10.1016/j.radonc.2004.11.003. Epub 2004 Nov 25. Radiother Oncol. 2005. PMID: 15878099 Clinical Trial.
-
Clinical radiobiology of stage T2-T3 bladder cancer.Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):60-70. doi: 10.1016/j.ijrobp.2004.02.056. Int J Radiat Oncol Biol Phys. 2004. PMID: 15337540
-
Cell repopulation and overall treatment time.Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):1071-5. doi: 10.1016/0360-3016(90)90036-j. Int J Radiat Oncol Biol Phys. 1990. PMID: 2211245 Review.
-
Effect of radiation fraction size on local control rates for early glottic carcinoma. A model analysis for in vivo tumor growth and radio-response parameters.Arch Otolaryngol Head Neck Surg. 1994 Jul;120(7):737-42. doi: 10.1001/archotol.1994.01880310041008. Arch Otolaryngol Head Neck Surg. 1994. PMID: 8018326 Review.
Cited by
-
Linear quadratic and tumour control probability modelling in external beam radiotherapy.J Math Biol. 2009 Apr;58(4-5):799-817. doi: 10.1007/s00285-008-0222-y. Epub 2008 Sep 30. J Math Biol. 2009. PMID: 18825382 Review.
-
Muscle-invasive bladder cancer treated with TURB followed by concomitant boost with small reduction of radiotherapy field with or without of chemotherapy.Rep Pract Oncol Radiother. 2016 Jan-Feb;21(1):31-6. doi: 10.1016/j.rpor.2015.09.001. Epub 2015 Sep 29. Rep Pract Oncol Radiother. 2016. PMID: 26900355 Free PMC article.
-
Combined chemotherapy and external beam radiotherapy for transitional cell carcinoma of the bladder.Curr Oncol Rep. 2004 May;6(3):230-6. doi: 10.1007/s11912-004-0054-x. Curr Oncol Rep. 2004. PMID: 15066235 Review.
-
Could Concurrent Capecitabine with Hypofractionated Radiotherapy in Elderly Patients with Muscle-Invasive Bladder Cancer be an Option?Asian Pac J Cancer Prev. 2022 May 1;23(5):1733-1740. doi: 10.31557/APJCP.2022.23.5.1733. Asian Pac J Cancer Prev. 2022. PMID: 35633559 Free PMC article.
-
Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts.J Neurooncol. 2006 Jan;76(1):31-8. doi: 10.1007/s11060-005-3666-6. J Neurooncol. 2006. PMID: 16311843
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical